ALAVERT Drug Patent Profile
✉ Email this page to a colleague
When do Alavert patents expire, and when can generic versions of Alavert launch?
Alavert is a drug marketed by Fdn Consumer and is included in one NDA.
The generic ingredient in ALAVERT is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alavert
A generic version of ALAVERT was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALAVERT?
- What are the global sales for ALAVERT?
- What is Average Wholesale Price for ALAVERT?
Summary for ALAVERT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 148 |
| Patent Applications: | 3,954 |
| What excipients (inactive ingredients) are in ALAVERT? | ALAVERT excipients list |
| DailyMed Link: | ALAVERT at DailyMed |
US Patents and Regulatory Information for ALAVERT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fdn Consumer | ALAVERT | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 021375-001 | Dec 19, 2002 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
